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the differences were not statistically signiﬁcant. CONCLUSION:
Study results largely correspond to previous published esti-
mates (i.e., Trussell, 2004). Contraception failure rates for user-
dependent methods were substantially greater in a Medicaid
population than those in a non-Medicaid plan. The efﬁcacy rates
of non-daily methods were not statistically different across the
two populations and thus may be the more appropriate option
for a Medicaid patient or other patient subpopulations shown to
have compliance issues.
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OBJECTIVE: Most studies of potentially inappropriate medica-
tions (PIMs) among older adults have focused on prevalence
rather than incidence. This study determined one-year incidence
of PIMs use among Indiana Medicaid beneﬁciaries 65 years old
or older who resided in nursing homes and examined associa-
tions between incident PIM use and hospitalizations and mortal-
ity. METHODS: A retrospective analysis was conducted using
Indiana Medicaid claims and enrollment ﬁles. Individuals were
included in the sample if they were 65 years old or older, received
Medicaid covered nursing home services from October 2002
through 12 months after starting a PIM in 2003 or until death in
2003, and were prescribed at least one new medication in 2003.
Individuals who received any PIM in the three months prior to
January 2003 were excluded. The 2003 Beers criteria were used
to identify PIMs. Associations between incident PIM use, hospi-
talization and mortality were assessed using logistic regression
models that controlled for age, gender, race, marital status,
Charlson comorbidity scores, number of medications prescribed
in 2003, and nursing home location. Selection bias was examined
using seemingly unrelated bivariate probit models. STATA
Intercooled for Windows was used for all statistical analyses.
RESULTS: The study sample consisted of 7594 individuals. One-
year incidence PIM use was 42.1%. Rhos, correlations of error
terms from equations predicting hospitalizations and mortality,
were not signiﬁcant indicating no selection bias. Incident PIM
users were more likely to be hospitalized (odds ratio
{OR} = 1.27, 95% C.I. 1.10–1.47) and more likely to die
(OR = 1.45, 95% C.I. 1.31–1.61) in 12 months after controlling
for demographic and clinical characteristics. CONCLUSION:
Incidence of PIM prescribing was high among elderly Indiana
Medicaid beneﬁciaries residing in nursing homes. Individuals
who began use of a PIM in 2003 were at a higher risk of
hospitalization and at higher risk of dying.
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OBJECTIVE: Comparison of data collected in a electronic
medical record (EMR) database on men age 21 years and older
with and without erectile dysfunction (ED) on concomitant drug
prescription, co-morbid conditions, smoking status and BMI.
METHODS: A retrospective review of the General Electric
Centricity MQIC research database containing the ambulatory
health records of US patients was conducted. ED patients age 21
and older were identiﬁed by diagnosis, PDE5 and/or both; 18
month of activity and smoking status was required. Two non-ED
age-matched (within +/-2 years) controls were randomly selected
for and linked to each case. A matched case-control analysis was
conducted using conditional logistic regression, with goodness of
ﬁt and residual analyses used to test validity and assumptions.
RESULTS: Non-smokers compared to current smokers were less
likely to develop ED. There was an increase odds of ED with each
unit increase in BMI. Men with BMI 30–39.9 had the highest risk
of ED (2.14 OR, 1.73–2.64 95% CI) compared to those with
BMI  18.5. Antihypertensive, lipid lowering agents and diuret-
ics had the highest relative odds for ED respectively (2.43 OR,
2.34–2.5 95% CI; 1.57 OR, 1.52–1.62 95% CI; 1.44 OR, 1.37–
1.5 95% CI). None of the other risk factors or co-morbid con-
ditions (cerebrovascular disease, kidney disease, anti-
arrhythmics, and anti-neoplastics) was found to increase the risk
of ED. CONCLUSION: EMR data provides a means for assess-
ing risk factors for and associated conditions consistent with ED
in a real-world setting, including the links between this condition
and commonly used prescription drugs. The likelihood of devel-
oping ED was less for non-smokers and increased with increasing
BMI and the use of antihypertensives, lipid lowering agents and
diuretics.
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OBJECTIVE: To generate national estimates of the effect of
injury severity on the incidence and associated resource
utilization-related outcomes of deep vein thrombosis (DVT)
among pediatric traumatic injury inpatient admissions in the
United States. METHODS: Data from the 2003 HCUP
KID dataset were analyzed for 240,387 hospital stays
(unweighted = 146,512) for traumatic injury in patients 20
years old. Among these hospitalizations, cases of DVT were
identiﬁed. Injury severity scores (ISS) were calculated using the
ICDMAP90 software; four mutually exclusive categories corre-
sponding to increasing severity were created. Weighted regression
models estimated the effect of injury severity on the likelihood of
DVT, controlling for patient- and hospital-speciﬁc characteris-
tics. Additional models including interaction terms for DVT/
injury severity category estimated the joint effect of these
parameters on total costs and LOS. RESULTS: Among traumatic
injuries identiﬁed, 648 patients (0.27%) had an ICD-9-CM
code consistent with DVT, similar to previous estimates in the
literature. Among observations with complete data, moderate
[ISS = 9–15], severe [ISS = 16–24] and critical [ISS = 25+])
injuries increased the likelihood of DVT (Odds Ratio
[p-value] = 2.13 [<0.0001], 2.49 [0.0001], and 3.53 [<0.0001],
respectively), as compared to minor injuries (ISS = 0–8). Relative
to minor injuries, severe and critical injuries among those with
DVT (i.e., interactive effects) were associated with increased
LOS. DVT and increasing severity each independently increased
total costs, but interactive effects were not signiﬁcant. CONCLU-
SION: In this study we quantify the effect of injury severity on
the incidence and utilization-related outcomes of DVT among
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those with traumatic injury in a multi-payer US population.
Increasing severity appears to increase the likelihood of develop-
ing a DVT. Further, new interventions that mitigate the develop-
ment of DVT may reduce the economic burden of traumatic
injury among pediatric hospitalizations. Clinicians and other
decision makers should be aware of the relationship between
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OBJECTIVE: Medications used to control DM2 and hyperten-
sion are common associated with ED problems. This had affected
adherence and therefore the long-term control of Mexican
patients with those diseases, increasing long-term complications
and health care costs. The purpose of the study was to evaluate
the cost-effectiveness of using ED treatments as adjuvant thera-
pies in patients with DM2 and hypertension from an institutional
perspective. METHODS: A cost-effectiveness assessment was
performed employing a ten-years decision tree model. Compara-
tors used in the model were Sildenaﬁl (50 mg/day-100 mg/day);
Taladaﬁl (20 mg/day) and Vardenaﬁl (10 mg/day-20 mg/day).
Effectiveness measure used was the number of hospitalization
avoided related to uncontrolled-patients due to ED causes. The
transition probabilities were obtained from international pub-
lished literature and a local survey, previously validated, related
to ED problems in Mexican patients(n = 146 with DM2; n = 326
with hypertension) at multiple second-level Hospitals within the
Social Security Mexican Institute (IMSS). Resource use data was
obtained from hospital records(n = 1000) and a 3% discount
rate was used. The model was calibrated according to interna-
tional guidelines. Probabilistic sensitivity analyses were per-
formed using bootstrapping techniques. RESULTS: Savings per
patient with DM2 were US$816.70 for sildenaﬁl 50 mg/day;
US$668.30 for sildenaﬁl 100 mg/day; US$711.20 for tadalaﬁl;
US$646.30 for vardenaﬁl 10 mg/day and US$603.50 for vard-
enaﬁl 20 mg/day. Annual mean savings per patient with hyper-
tension resulted in US$1627.00; US$1447.50, US$1520.80,
US$1444.50 and US$1432.20; respectively following the order
above. Patients treated with ED therapies avoided signiﬁcant
number of hospitalizations (complications) in both diseases and
sildenaﬁl 50 mg/day was the therapy which showed the higher
number of hospitalizations avoided(23 for DM2 and 25 for
hypertension). ICER’s showed Sildenaﬁl 50 mg/day as the domi-
nant treatment. The results were robust to probabilistic sensi-
tivity analyses and acceptability curves. CONCLUSION: ED
therapies should be employed in males who show this pro-
blem secondary to DM2 and hypertension. These results could be
used by Mexican decision-makers to generate cost-containment
strategies.
PIH7
BURDEN OF ILLNESS OF HYPERTENSION AMONGWOMEN
USING MENOPAUSAL HORMONETHERAPY
Pelletier E1, Gricar JA2, Chang J3, Nahum GG3, Mittapally R1
1IMS Health,Watertown, MA, USA, 2Independent HealthCare
Consultant, New York, NY, USA, 3Bayer HealthCare Pharmaceuticals,
Wayne, NJ, USA
OBJECTIVE: High blood pressure is common in menopausal
women and some hormone therapies (HT) for menopause may
contribute to increased blood pressure. However, the burden of
illness (BOI) of hypertension in women receiving menopausal HT
is not well-documented in the current literature. This study esti-
mates the prevalence and economic burden of hypertension in
this patient population. METHODS: Patients with at least one
prescription for menopausal HT were selected from the Phar-
Metrics database during the period from July 1, 2003–June 30,
2005. HT patients were divided into those with and without
hypertension. The non-hypertensive cohort was propensity score
matched to the hypertensive cohort, controlling for patient
demographics, overall comorbidities, and type of HT use. The
BOI of hypertension was deﬁned as the difference in average
annual total health care expenditures per person between the
cohorts. RESULTS: The prevalence of menopausal HT use was
9.75% among potentially eligible patients in this commercially-
insured sample. Hypertension was the most common comorbid-
ity, with a prevalence of 34%. HT patients with hypertension
(n = 106,729) had signiﬁcantly higher average annual health
care expenditures compared with matched HT patients without
hypertension ($8,908 versus $5,960; difference of $2,948;
P < 0.001). Less than 1% was due to differences in menopause-
related care between the cohorts; 54% was attributable to
hypertension-related care and 45% to the care of other common
comorbidities, such as lipid disorders. CONCLUSION: Hyper-
tension is the most common comorbidity among commercially-
insured menopausal hormone therapy users in the United States.
The annual incremental BOI of hypertension among HT users is
both substantial and statistically signiﬁcant, averaging $2,948
per patient per year. Given the number of menopausal women
who use HT and the prevalence of hypertension in this cohort,
employers and medical care payers should be interested in ﬁnding
ways to lessen the burden associated with hypertension.
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COST-EFFECTIVENESS OF ORAL ANDTRANSDERMAL
CONTRACEPTIVES
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OBJECTIVE: In Ukraine the State program «Reproductive
health of the nation for the period till 2015», providing reduction
in the quantity of abortions is authorized, using hormonal con-
traception. The aim was to identify the most cost-effective oral
or transdermal contraceptives using a provider perspective.
METHODS: A decision tree was developed to compare the cost-
effectiveness of oral contraceptive 3 mg drospirenone/0.03 mg
ethinylestradiol (D-E) vs. 0.25 mg norgestimate/0.035 mg
ethynilestradiol (NA-E) vs. transdermal contraceptive 6 mg
norelgestromin/0.6 mg ethynilestradiol (transdermal N-E) for
preventing a pregnancy per patient per year. Direct medical
cost were based on average wholesale prices for medicines
(01.10.2007), ans physician, laboratory costs based on tariffs of
Lviv family planning center. Probability data that included com-
pliance and pregnancy rates were extracted from randomized
clinical trials and public resources. A probablistic sensitivity
analysis of free parameters was conducted through a Monte-
Carlo simulation. Key parameters were sampled from beta
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